BTOG relies solely on income from exhibition/sponsorship at education events and annual conference registration fees to allow it to support and educate thoracic oncology health care professionals and to undertake key activities under our three strategic arms – education, research and representation. Sponsorship does not constitute endorsement, recommendation, or favouring by BTOG.
Diamond Sponsor for 2023
For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world. For more information about our products and to register with MSD Connect, visit www.msdconnect.co.uk (this link will direct you to an MSD promotional website). For more information about MSD, visit www.msd-uk.com and connect with us @MSDintheUK on Twitter, Instagram, LinkedIn, YouTube and Facebook.
Platinum Sponsors for 2023
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca is based in five different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. For more information, please visit www.astrazeneca.co.uk and follow us on Twitter at @AstraZenecaUK
Bayer plc aims to develop products that improve people’s quality of life. We concentrate on the research and development of innovative drugs and novel therapeutic approaches to prioritise targets and pathways with the potential to impact not just the treatment of common cancers, but rarer cancers as well. UK healthcare professionals and other relevant UK decision makers can register here to subscribe to electronic communications about Bayer's products, services and events: https://hcpregistration.bayer.co.uk/ Visit https://oncology.bayer.co.uk/ for more information.
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients. https://www.bms.com/gb
At Janssen, we envision a world where cancer is a potentially preventable, chronic, or curable disease. To reach this goal, we aim to fundamentally alter the way cancer is understood, diagnosed, and managed. Cancer interception is one of our key strategies for meeting this challenge head on. It means achieving a more robust understanding of the mechanisms involved in the transition of normal cells to a pre-malignant state, offering an opportunity to develop treatments with the potential to stop cancer in its earliest stages.
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. At Lilly, we are dedicated to developing and delivering innovative medicines that will make a meaningful difference to cancer patients. For us, this means putting an intense focus on the latest scientific advances and collaborating with doctors, other researchers, advocates and payers to ensure our medicines bring value to people living with cancer. People living with cancer are at the centre of what we do. We believe health care makes a difference when striving to improve peoples’ lives. Whether it's treating rare tumour types, leveraging precision medicine, continuing the study of immuno-oncology or discovering new ways to advance existing treatments, we're dedicated to making even greater differences in the lives of people living.
Merck is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumour types in gastrointestinal, genitourinary, and thoracic cancers. Our curiosity drives our pursuit of treatments for even the most complex cancers, as we work to illuminate a path to scientific breakthroughs that transform patient outcomes. Learn more at https://www.merckgroup.com/uk-en
At Pfizer, we aim to apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry leading portfolio of over 15 approved innovative cancer medicines and biosimilars in the UK.
In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS. To learn more about our commitments, please visit us online at www.Pfizer.co.uk or follow us on Twitter (@Pfizer_UK), Facebook (@PfizerUK) and Instagram (@pfizeruk).
Roche is a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people’s lives. We have created truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. In the UK we employ over 2,000 people who work hard every day to bring our medicines and diagnostics to people who urgently need them. We work from bench to bedside - researching new medicines and diagnostics, running global clinical trials, and collaborating with the NHS to try to ensure rapid uptake and delivery of our products and services. For more information: www.roche.co.uk
At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialisation to rapidly meet the needs of the cancer community, optimising our ability to bring transformative medicines to patients. Our demonstrated leadership in the treatment of haematologic cancers and solid tumours combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide. https://www.takeda.com/en-gb/
Gold Sponsors for 2023
For Amgen, the key to serving patients is by being the best possible partner to the NHS and the professionals that fuel it. Over the last 40 years, Amgen has developed innovative medicines in cancer and long-term conditions and is immensely proud of the difference made to the lives of people in the UK through these and the services we deliver alongside them, enabling even more value for the system and patients. Committed to driving sustainable solutions that can adapt to an ever-evolving health system, Amgen is proud to serve its people, customers, and patients every day. www.amgen.co.uk
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant360 liquid biopsy comprehensive genomic profiling test is the leading, analytically, and clinically validated liquid biopsy assay that effectively detects the four main classes of genomic alterations in 74 well-documented cancer genes, thereby enabling clinicians to identify candidates for targeted therapies and to avoid treatments which are less likely to be effective. It is indicated for all advanced solid tumours, both in first line and at progression. Guardant360 includes most guideline recommended genomic biomarkers, in line with those included on the National Genomic Test Directory, and has a very fast turnaround time, with an average of 7 days from sample receipt in the laboratory to issuing of the report. The test is performed in a single CLIA certified and CAP and ISO15189 accredited central laboratory in Redwood City, California. Since being introduced, Guardant360 has become widely adopted in clinical practice and there are now more than 260 peer-reviewed publications, over 60 of which describe the outcomes achieved when patients are treated in line with their molecular tumour profile identified through Guardant360. The test has been used by over 11,000 oncologists, with more than 250,000 tests performed to date. www.guardanthealth.eu
Silver Sponsors for 2023
Irwin Mitchell has been at the forefront of recovering compensation to improve quality of life and provide for the holistic needs of our clients with asbestos diseases for many decades. Our dedicated and compassionate, specialist lawyers, are leaders in their field, have won many landmark cases, including one of the first to fund the costs of private medical treatments, winning many Appeal Court cases over the decades and fighting for positive changes in the law. We support our clients and their healthcare professionals to optimise the quality of life of our clients and their families. To find out how we can help you or your patients, speak with one of our specialist lawyers. We cover the whole of the UK - you can call us on 0808 149 8004 or contact us online www.irwinmitchell.com/.
Leigh Day has specialised in asbestos cases for over 25 years, both in the UK and across the globe. Our Lawyers have represented thousands of clients. We advise our clients on a ‘no win, no fee’ basis and they keep 100% of their compensation. We visit our clients at their home or wherever they may be. We have built up good relationships with Medical Practitioners and Court Experts and we are well known and respected within this area of law. Leigh Day lawyers not only represent clients who have developed an illness but they also have shaped the law through landmark rulings in the Supreme Court which have set precedents which other law firms follow.In addition we were instructed by the leading asbestos expert Dr. Robin Rudd who brought a claim against John Bridle, an asbestos lobbyist who claims chrysotile products are safe. A higher number of Leigh Day lawyers are ranked in Band 1 than any other law firm, in the independent legal directory Chambers & Partners. One of our lawyers has raised over £60,000 for research to find a cure for mesothelioma, as her father died from mesothelioma. Click to download our Guide for Patients: https://www.leighday.co.uk/media/hd4le4fd/digital_ld-mesothelioma-asbestos-booklet-may2021.pdf